Erasca, Inc. (ERAS)
NASDAQ: ERAS · Real-Time Price · USD
9.96
-9.19 (-47.99%)
Apr 28, 2026, 2:54 PM EDT - Market open
Erasca Employees
Erasca had 103 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
103
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,209,184
Market Cap
3.10B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 103 | 0 | - |
| Dec 31, 2024 | 103 | -23 | -18.25% |
| Dec 31, 2023 | 126 | -3 | -2.33% |
| Dec 31, 2022 | 129 | 6 | 4.88% |
| Dec 31, 2021 | 123 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Rhythm Pharmaceuticals | 414 |
| Apogee Therapeutics | 261 |
| Cogent Biosciences | 258 |
| Kymera Therapeutics | 238 |
| Arcellx | 209 |
| Celcuity | 155 |
| Protagonist Therapeutics | 132 |
| Centessa Pharmaceuticals | 118 |
ERAS News
- 2 hours ago - Erasca Stock Sinks 50% in Race for ‘Miracle' Cancer Drug. What's Behind the Historic Sell-Off. - Barrons
- 4 hours ago - Erasca, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 5 hours ago - Why Is Cancer Drug Developer Erasca Stock Plunging On Tuesday? - Benzinga
- 8 hours ago - Erasca shares sink after patient death in early-stage cancer drug trial - Reuters
- 22 hours ago - Erasca Transcript: Study result - Transcripts
- 22 hours ago - Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors - GlobeNewsWire
- 1 day ago - Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 - GlobeNewsWire
- 6 weeks ago - Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results - GlobeNewsWire